Royce & Associates’s Vanda Pharmaceuticals VNDA Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,821	Closed	-$94.7K	–	957
2022 Q4	$94.7K	Sell	12,821 -10,334	-45%	-$101K	﹤0.01%	890
2022 Q3	$229K	Sell	23,155 -52,908	-70%	-$559K	﹤0.01%	879
2022 Q2	$829K	Sell	76,063 -163,564	-68%	-$1.69M	0.01%	778
2022 Q1	$2.71M	Buy	239,627 +119,329	+99%	+$1.57M	0.02%	670
2021 Q4	$1.89M	Sell	120,298 -5,119	-4%	-$89.2K	0.01%	734
2021 Q3	$2.15M	Sell	125,417 -7,994	-6%	-$140K	0.02%	734
2021 Q2	$2.87M	Sell	133,411 -3,347	-2%	-$59.9K	0.02%	704
2021 Q1	$2.05M	Buy	136,758 +3,369	+3%	+$54.5K	0.01%	751
2020 Q4	$1.75M	Buy	133,389 +63,841	+92%	+$768K	0.01%	750
2020 Q3	$672K	Buy	69,548 +35,342	+103%	+$378K	0.01%	822
2020 Q2	$391K	Buy	34,206 +5,919	+21%	+$67K	﹤0.01%	881
2020 Q1	$293K	Buy	28,287 +808	+3%	+$10K	﹤0.01%	886
2019 Q4	$451K	Buy	27,479 +13,193	+92%	+$199K	﹤0.01%	901
2019 Q3	$190K	Buy	+14,286	New	+$199K	﹤0.01%	980